U.S. regulators are preparing an appeal of a recent court decision that barred the Food and Drug Administration from granting shared 180-day exclusivity to several makers of generic versions of branded drugs.
GlaxoSmithKline is suing Israeli drug maker Dexxon in the Tel Aviv District Court, asking the court to bar the use of the name Zanidex for a generic version of its Zantac indigestion drug.
In a move that could have broad ramifications for 505 (b) (2) generic drug approvals, the FDA has stayed its decision to allow Dr. Reddy's to market a generic version of Pfizer’s anti-hypertension drug Norvasc.
GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine.
AstraZeneca has filed a lawsuit in the U.S. District Court for the District of Delaware against Andrx for patent infringement over the generic drug maker’s plans to make a generic version of hypertension drug Troprol-XL.
Two years after a judge overturned Guidant Corp.’s $140 million jury award from rival St. Jude Medical Inc. after a witness lied on the stand, the medical device maker has filed yet another patent infringement lawsuit against its Canadian competitor.
The U.S. Court of Appeals for the Federal Circuit has vacated a lower court’s decision that supported Israeli generics maker Teva's right to sell a generic form of Schwarz Pharma’s hypertension drug Univasc.
Boston Scientific and Johnson & Johnson will face off in court in June 2005 in their litigation over the lucrative market for drug-eluting stents.
Japanese pharmaceutical company Eisai has filed a lawsuit in the U.S. District Court for the Southern District of New York against generics maker Mylan Laboratories over its abbreviated new drug application for a generic version of ulcer medicine Aciphex.
Edwards Lifesciences Corp. settled a lawsuit against rival Carbomedics, Inc. over medical technologies for heart valve repair and replacement.
The Court of Appeals for the Federal Circuit has upheld a lower court’s decision against GlaxoSmithKline over generics maker Impax Laboratories’ abbreviated new drug applications for certain dosages of Wellbutrin and Zyban.
Urologix has settled its lawsuit against Swedish rival ProstaLund and ACMI Corporation over two of Urologix' patents for microwave treatment for benign prostatic hyperplasia.
U.S. Representative W.J. "Billy" Tauzin is close a decision on whether to take over the helm at the pharmaceutical industry's trade association, after turning down an offer to succeed Jack Valenti as the film industry's top lobbyist, according to reports.
A federal court in Indiana will hear arguments Monday in the high-stakes battle for Eli Lilly’s top-selling drug, the $4.3-billion-a-year schizophrenia medicine Zyprexa.
A U.S. judge has revived biotechnology company Corixa Corp.'s lawsuit against rival Biogen Idec Inc. over patents for Corixa’s Bexxar cancer drug.
Israeli pharmaceutical companies Lumenis Ltd. and Syneron Medical Ltd. settled their U.S. and Israeli litigation over patents for the use of incoherent light in aesthetic and medical applications, the two companies said Wednesday.
A New York judge denied summary judgment in Pfizer’s lawsuit against defunct IP boutique Pennie & Edmonds, but ruled the firm had broken disciplinary rules and reported it to the Disciplinary Committee.
The U.S. District Appeals Court for the District of Columbia rejected a challenge from generic drug maker Apotex and upheld rival Alpharma’s 180-day marketing exclusivity period for gabapentin capsules.
U.S. congressional lawmakers have sent letters to five of the nation's largest drug makers, asking them to explain what they are doing to stop counterfeit drugs from entering the market.
West Coast intellectual property boutique Townsend and Townsend and Crew LLP promoted eight attorneys to partner, matching last year’s record for the largest new partner class in the firm’s history.